0000000000007779

AUTHOR

Lluís Masmiquel

showing 3 related works from this author

Prevention, diagnosis, and treatment of obesity. 2016 position statement of the Spanish Society for the Study of Obesity.

2017

Position statementAdultMaleSpanish Society for the Study of ObesityPALABRASPediatricsmedicine.medical_specialtyPediatric ObesityMEDLINEBariatric SurgeryComorbidity030204 cardiovascular system & hematologyModels BiologicalComorbidities03 medical and health sciencesDisease susceptibility0302 clinical medicineSleep Apnea SyndromesDiabetes mellitusDiagnosismedicinePrevalenceHumans030212 general & internal medicineObesityChildExerciseAdiposityDyslipidemiasInflammationbusiness.industryPreventionmedicine.diseaseObesityComorbidityDietTreatmentDiabetes Mellitus Type 2Cardiovascular DiseasesSpainBody CompositionFemaleAnti-Obesity AgentsDisease SusceptibilitybusinessEnergy IntakeEndocrinologia, diabetes y nutricion
researchProduct

Prevención, diagnóstico y tratamiento de la obesidad. Posicionamiento de la Sociedad Española para el Estudio de la Obesidad de 2016

2017

03 medical and health sciences0302 clinical medicineNutrition and DieteticsEndocrinologybusiness.industryEndocrinology Diabetes and MetabolismMedicine030209 endocrinology & metabolism030212 general & internal medicinebusinessEndocrinología, Diabetes y Nutrición
researchProduct

Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre st…

2016

Ajuda rebuda: GlaxoSmithKline Several glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1Ra) have been made recently available in Spain for type 2 diabetes mellitus (DM2) treatment. There are no published data on the clinical and sociodemographic profile of patients initiating treatment with GLP-1Ra in Spain. Our objective was to understand these patients' characteristics in a real-world clinical practice setting. Design. Cross-sectional observational study. Setting. Spanish specialist outpatient clinics.Participants 403 adults with DM2 initiating GLP-1Ra treatment were included. Primary and secondary outcome measures Sociodemographic and DM2-related clinical data, including treatment …

medicine.medical_specialtyDM2Cross-sectional studymedicine.medical_treatment030209 endocrinology & metabolism03 medical and health sciences0302 clinical medicineInsulinaInternal medicinemedicineOutpatient clinic030212 general & internal medicineMedical prescriptionGlucagon-like peptide 1 receptorDiabetisbusiness.industryInsulinDiabetis mellitus tipus 2Type 2 Diabetes MellitusGeneral MedicineDiabetes mellitus tipo 2EndocrinologyConcomitantMalalties d'origen nutricionalbusinessBody mass index
researchProduct